[{"orgOrder":0,"company":"Beijing Avistone Pharmaceuticals Biotechnology","sponsor":"SDIC CS Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"Vebreltinib","moa":"||c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Beijing Avistone Pharmaceuticals Biotechnology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Beijing Avistone Pharmaceuticals Biotechnology \/ SDIC CS Capital","highestDevelopmentStatusID":"15","companyTruncated":"Beijing Avistone Pharmaceuticals Biotechnology \/ SDIC CS Capital"},{"orgOrder":0,"company":"Beijing Avistone Pharmaceuticals Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vebreltinib","moa":"||c-Met receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Beijing Avistone Pharmaceuticals Biotechnology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Beijing Avistone Pharmaceuticals Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Beijing Avistone Pharmaceuticals Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Avistone Pharmaceuticals Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||c-Met receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Beijing Avistone Pharmaceuticals Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Beijing Avistone Pharmaceuticals Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Avistone Pharmaceuticals Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Avistone Pharmaceuticals Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Vebreltinib","moa":"||tyrosine kinase inhibitors","graph1":"Oncology","graph2":"Phase III","graph3":"Beijing Avistone Pharmaceuticals Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Beijing Avistone Pharmaceuticals Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Avistone Pharmaceuticals Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Avistone Pharmaceuticals Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||c-Met receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Beijing Avistone Pharmaceuticals Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Beijing Avistone Pharmaceuticals Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Avistone Pharmaceuticals Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Avistone Pharmaceuticals Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vebreltinib","moa":"||tyrosine kinase inhibitors","graph1":"Oncology","graph2":"Phase III","graph3":"Beijing Avistone Pharmaceuticals Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Beijing Avistone Pharmaceuticals Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Avistone Pharmaceuticals Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Avistone Pharmaceuticals Biotechnology","sponsor":"Beijing Avistone Pharmaceuticals Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Vebreltinib","moa":"||tyrosine kinase inhibitors","graph1":"Oncology","graph2":"Phase II","graph3":"Beijing Avistone Pharmaceuticals Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Beijing Avistone Pharmaceuticals Biotechnology \/ Beijing Avistone Biotechnology","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Avistone Pharmaceuticals Biotechnology \/ Beijing Avistone Biotechnology"},{"orgOrder":0,"company":"Beijing Avistone Pharmaceuticals Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ANS014004","moa":"||Type-2 c-met tyrosine kinase","graph1":"Oncology","graph2":"Phase I","graph3":"Beijing Avistone Pharmaceuticals Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Beijing Avistone Pharmaceuticals Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Beijing Avistone Pharmaceuticals Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Avistone Pharmaceuticals Biotechnology","sponsor":"Shanghai Chest Hospital | Hunan Cancer Hospital | Henan Cancer Hospital | Zhejiang Cancer Hospital | Peking University Cancer Hospital & Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ANS014004","moa":"||Type-2 c-met tyrosine kinase","graph1":"Oncology","graph2":"Phase I","graph3":"Beijing Avistone Pharmaceuticals Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Beijing Avistone Pharmaceuticals Biotechnology \/ Shanghai Chest Hospital | Hunan Cancer Hospital | Henan Cancer Hospital | Zhejiang Cancer Hospital | Peking University Cancer Hospital & Institute","highestDevelopmentStatusID":"6","companyTruncated":"Beijing Avistone Pharmaceuticals Biotechnology \/ Shanghai Chest Hospital | Hunan Cancer Hospital | Henan Cancer Hospital | Zhejiang Cancer Hospital | Peking University Cancer Hospital & Institute"},{"orgOrder":0,"company":"Beijing Avistone Pharmaceuticals Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||c-Met receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Beijing Avistone Pharmaceuticals Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Beijing Avistone Pharmaceuticals Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Avistone Pharmaceuticals Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Avistone Pharmaceuticals Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||c-Met receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Beijing Avistone Pharmaceuticals Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Beijing Avistone Pharmaceuticals Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Avistone Pharmaceuticals Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Avistone Pharmaceuticals Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ANS03","moa":"||TYK","graph1":"Oncology","graph2":"IND Enabling","graph3":"Beijing Avistone Pharmaceuticals Biotechnology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Beijing Avistone Pharmaceuticals Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Beijing Avistone Pharmaceuticals Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Avistone Pharmaceuticals Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vebreltinib","moa":"||tyrosine kinase inhibitors","graph1":"Oncology","graph2":"Phase III","graph3":"Beijing Avistone Pharmaceuticals Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Avistone Pharmaceuticals Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Avistone Pharmaceuticals Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Avistone Pharmaceuticals Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ANS03","moa":"||TYK","graph1":"Oncology","graph2":"Phase I","graph3":"Beijing Avistone Pharmaceuticals Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Avistone Pharmaceuticals Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Beijing Avistone Pharmaceuticals Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Beijing Avistone Pharmaceuticals Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ANS014004","moa":"||Type-2 c-met tyrosine kinase","graph1":"Oncology","graph2":"Phase I","graph3":"Beijing Avistone Pharmaceuticals Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Avistone Pharmaceuticals Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Beijing Avistone Pharmaceuticals Biotechnology \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals by Beijing Avistone Pharmaceuticals Biotechnology
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
